Norcantharidin inhibits growth of human gallbladder carcinoma xenografted tumors in nude mice by inducing apoptosis and blocking the cell cycle in vivo

Hepatobiliary and Pancreatic Diseases International

Volumn 9, Issue 4, 2010, Pages 414-422

  Fan, Yue Zu ^a   Zhao, Ze Ming ^a   Fu, Jin Ye ^b   Chen, Chun Qiu ^a   Sun, Wei ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; Gallbladder neoplasm; Norcantharidin; Tumor growth

Indexed keywords

BIOTIN; CYCLIN D1; NORCANTHARIDIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P27; STREPTAVIDIN; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; FLOW CYTOMETRY; GALLBLADDER CARCINOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BICYCLO COMPOUNDS, HETEROCYCLIC; CARCINOMA; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN; CYCLIN D1; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955608840     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E, Salemis NS. Gallbladder cancer. Am J Surg 2008;196:252-264.
2. Reddy SK, Clary BM. Surgical management of gallbladder cancer. Surg Oncol Clin N Am 2009;18:307-324, ix.
3. Shukla PJ, Barreto SG. Gallbladder cancer: we need to do better! Ann Surg Oncol 2009;16:2084-2085.
4. Lazcano-Ponce EC, Miquel JF, Munoz N, Herrero R, Ferrecio C, Wistuba II, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001;51:349-364.
5. Li LD, Zhang SW, Lu FZ, Mu R, Sun XD, Huangpu XM. Research on characteristics of mortality spectrum and type composition of malignant tumors in China. Zhonghua Zhong Liu Za Zhi 1997;19:323-328.
6. Wang BS, Qin J, Deng J, Zhang BH, Han TQ, Shen MC, et al. A survey on the diagnosis and treatment of biliary tract cancers in Shanghai. Zhonghua Wai Ke Za Zhi 2005;43:455-459.
7. Chakravarty KD, Yeh CN, Jan YY, Chen MF. Factors influencing long-term survival in patients with T3 gallbladder adenocarcinoma. Digestion 2009;79:151-157.
8. Konstantinidis IT, Deshpande V, Genevay M, Berger D, Fernandez-del Castillo C, Tanabe KK, et al. Trends in presentation and survival for gallbladder cancer during a period of more than 4 decades: a single-institution experience. Arch Surg 2009;144:441-447.
9. Pilgrim C, Usatoff V, Evans PM. A review of the surgical strategies for the management of gallbladder carcinoma based on T stage and growth type of the tumour. Eur J Surg Oncol 2009;35:903-907.
10. Taner CB, Nagorney DM, Donohue JH. Surgical treatment of gallbladder cancer. J Gastrointest Surg 2004;8:83-89.
11. Singh S, Agarwal AK. Gallbladder cancer: the role of laparoscopy and radical resection. Ann Surg 2009;250:494-495.
12. Wang JD, Liu YB, Quan ZW, Li SG, Wang XF, Shen J. Role of regional lymphadenectomy in different stage of gallbladder carcinoma. Hepatogastroenterology 2009;56:593-596.
13. Hueman MT, Vollmer CM Jr, Pawlik TM. Evolving treatment strategies for gallbladder cancer. Ann Surg Oncol 2009;16:2101-2015.
14. Ishii H, Furuse J, Yonemoto N, Nagase M, Yoshino M, Sato T. Chemotherapy in the treatment of advanced gallbladder cancer. Oncology 2004;66:138-142.
15. Morine Y, Shimada M, Ikegami T, Imura S, Kanemura H, Arakawa Y, et al. Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients for unresectable biliary carcinoma. Hepatogastroenterology 2009;56:307-312.
16. Morise Z, Sugioka A, Tanahashi Y, Okabe Y, Ikeda M, Kagawa T, et al. Treatment of patients with unresectable advanced carcinoma of biliary tract-chemotherapy and surgical resection. Anticancer Res 2009;29:1783-1786.
17. Gold DG, Miller RC, Haddock MG, Gunderson LL, Quevedo F, Donohue JH, et al. Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience. Int J Radiat Oncol Biol Phys 2009;75:150-155.
18. Mahantshetty UM, Palled SR, Engineer R, Homkar G, Shrivastava SK, Shukla PJ. Adjuvant radiation therapy in gall bladder cancers: 10 years experience at Tata Memorial Hospital. J Cancer Res Ther 2006;2:52-56.
19. Kresl JJ, Schild SE, Henning GT, Gunderson LL, Donohue J, Pitot H, et al. Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys 2002;52:167-175.
20. Mojica P, Smith D, Ellenhorn J. Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease. J Surg Oncol 2007;96:8-13. (Pubitemid 47015442)
21. Wang GS. Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol 1989;26:147-162.
22. Liu J, Gao J, Liu X. Advances in the study of Cantharidin and its derivatives. Zhong Yao Cai 2003;26:453-455.
23. Ho YP, To KK, Au-Yeung SC, Wang X, Lin G, Han X. Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety. J Med Chem 2001;44:2065-2068.
24. Yang EB, Tang WY, Zhang K, Cheng LY, Mack PO. Norcantharidin inhibits growth of human HepG2 celltransplanted tumor in nude mice and prolongs host survival. Cancer Lett 1997;117:93-98.
25. Yi SN, Wass J, Vincent P, Iland H. Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro. Leuk Res 1991;15:883-886.
26. Kok SH, Hong CY, Kuo MY, Lee CH, Lee JJ, Lou IU, et al. Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes. Oral Oncol 2003;39:19-26.
27. Hong CY, Huang SC, Lin SK, Lee JJ, Chueh LL, Lee CH, et al. Norcantharidin-induced post-G(2)/M apoptosis is dependent on wild-type p53 gene. Biochem Biophys Res Commun 2000; 276:278-285.
28. Chen YN, Chen JC, Yin SC, Wang GS, Tsauer W, Hsu SF, et al. Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer 2002;100:158-165.
29. Chen YN, Cheng CC, Chen JC, Tsauer W, Hsu SL. Norcantharidin-induced apoptosis is via the extracellular signal-regulated kinase and c-Jun-NH2-terminal kinase signaling pathways in human hepatoma HepG2 cells. Br J Pharmacol 2003;140:461-470.
30. Peng F, Wei YQ, Tian L, Yang L, Zhao X, Lu Y, et al. Induction of apoptosis by norcantharidin in human colorectal carcinoma cell lines: involvement of the CD95 receptor/ligand. J Cancer Res Clin Oncol 2002;128:223-230.
31. Fan YZ, Fu JY, Zhao ZM, Chen CQ. The in vitro effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells and its mechanism. Zhonghua Zhong Liu Za Zhi 2004;26:271-274.
32. Fan YZ, Fu JY, Zhao ZM, Chen CQ. Effect of norcantharidin on proliferation and invasion of human gallbladder carcinoma GBC-SD cells. World J Gastroenterol 2005;11:2431-2437.
33. Fan YZ, Fu JY, Zhao ZM, Chen CQ. Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro. Hepatobiliary Pancreat Dis Int 2007;6:72-80.
34. Liao HF, Su SL, Chen YJ, Chou CH, Kuo CD. Norcantharidin preferentially induces apoptosis in human leukemic Jurkat cells without affecting viability of normal blood mononuclear cells. Food Chem Toxicol 2007;45:1678-1687.
35. Peng C, Liu X, Liu E, Xu K, Niu W, Chen R, et al. Norcantharidin induces HT-29 colon cancer cell apoptosis through the alphavbeta6-extracellular signal-related kinase signaling pathway. Cancer Sci 2009;100:2302-2308.
36. Chen YJ, Kuo CD, Tsai YM, Yu CC, Wang GS, Liao HF. Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells. Anticancer Drugs 2008;19:55-64.
37. Liu XH, Blazsek I, Comisso M, Legras S, Marion S, Quittet P, et al. Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells. Eur J Cancer 1995;31A:953-963.
38. McCluskey A, Ackland SP, Gardiner E, Walkom CC, Sakoff JA. The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design? Anticancer Drug Des 2001;16:291-303.
39. Hart ME, Chamberlin AR, Walkom C, Sakoff JA, McCluskey A. Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity. Bioorg Med Chem Lett 2004;14:1969-1973.
40. Li JL, Cai YC, Liu XH, Xian LJ. Norcantharidin inhibits DNA replication and induces apoptosis with the cleavage of initiation protein Cdc6 in HL-60 cells. Anticancer Drugs 2006;17:307-314.
41. Marx J. How cells cycle toward cancer. Science 1994;263: 319-321.
42. Chen YC, Chang SC, Wu MH, Chuang KA, Wu JY, Tsai WJ, et al. Norcantharidin reduced cyclins and cytokines production in human peripheral blood mononuclear cells. Life Sci 2009;84:218-226.
43. Hui AM, Li X, Shi YZ, Takayama T, Torzilli G, Makuuchi M. Cyclin D1 overexpression is a critical event in gallbladder carcinogenesis and independently predicts decreased survival for patients with gallbladder carcinoma. Clin Cancer Res 2000;6:4272-4277.
44. Hui AM, Li X, Shi YZ, Torzilli G, Takayama T, Makuuchi M. p27(Kip1) expression in normal epithelia, precancerous lesions, and carcinomas of the gallbladder: association with cancer progression and prognosis. Hepatology 2000;31:1068-1072.
45. Noguchi T, Kikuchi R, Ono K, Takeno S, Moriyama H, Uchida Y. Prognostic significance of p27/kip1 and apoptosis in patients with colorectal carcinoma. Oncol Rep 2003;10: 827-831.
46. Qiu Z, Zhu J, Harms JS, Friedrichsen J, Splitter GA. Bovine herpesvirus VP22 induces apoptosis in neuroblastoma cells by upregulating the expression ratio of Bax to Bcl-2. Hum Gene Ther 2005;16:101-108.
47. Zheng XL, Sun HX, Liu XL, Chen YX, Qian BC. Astilbic acid induced COLO 205 cell apoptosis by regulating Bcl-2 and Bax expression and activating caspase-3. Acta Pharmacol Sin 2004;25:1090-1095.
48. Bowen JM, Gibson RJ, Keefe DM, Cummins AG. Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 2005;37:56-62.
49. Kok SH, Cheng SJ, Hong CY, Lee JJ, Lin SK, Kuo YS, et al. Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio. Cancer Lett 2005;217:43-52.
50. Santini D, Tonini G, Vecchio FM, Borzomati D, Vincenzi B, Valeri S, et al. Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma. J Clin Pathol 2005;58:159-165.
51. Morinaga S, Nakamura Y, Ishiwa N, Yoshikawa T, Noguchi Y, Yamamoto Y, et al. Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma. Oncol Rep 2004;12: 1189-1194.
52. Dai DJ, Lu CD, Lai RY, Guo JM, Meng H, Chen WS, et al. Survivin antisense compound inhibits proliferation and promotes apoptosis in liver cancer cells. World J Gastroenterol 2005;11:193-199.